Benchmark reduced its price target and set a buy rating for Abbott Laboratories, while Royal Bank of Canada issued an outperform rating on July 29, 2026.
3 reports, 1 independent
Updated Oct 9
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Benchmark reduced its price target and set a buy rating for Abbott Laboratories, while Royal Bank of Canada issued an outperform rating on July 29, 2026.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Bank of America lowered its price target for Abbott stock.1 source
Benchmark reduced price target and set buy rating for Abbott Laboratories; RBC issued outperform rating.1 source
Keep exploring
The entities involved
-
Abbott Laboratories
American global health care and medical device products company
-
Benchmark
venture capital firm
-
Royal Bank of Canada
financial institution in Canada
Related events
- Charter Communications is the subject of new rating updates from Royal Bank of Canada, Bank of America, and Benchmark.
- Royal Bank of Canada decreased its price target for BOK Financial on October 17, 2026.
- Financial firms, including Rathbones and Jefferies, issued rating updates and consensus target prices on October 8, 2026.
- Royal Bank of Canada raised its target price for DCH.
- Ameren received coverage from Royal Bank of Canada and Scotiabank, which set price targets and ratings on October 14, 2026.